These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 10077416)

  • 1. Renoprotective effects of antihypertensive drugs.
    Preston RA
    Am J Hypertens; 1999 Jan; 12(1 Pt 2):19S-32S. PubMed ID: 10077416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. University of Miami Division of Clinical Pharmacology Therapeutic Rounds: managing hypertension in patients with kidney disease-implications for preservation of renal function.
    Preston RA; Fernandez L
    Am J Ther; 1998 Sep; 5(5):355-62. PubMed ID: 10099077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection.
    Locatelli F; Del Vecchio L; Andrulli S; Colzani S
    Kidney Int Suppl; 2002 Dec; (82):S53-60. PubMed ID: 12410856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
    Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
    Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on calcium antagonists and the kidney.
    Tobe S
    Curr Opin Nephrol Hypertens; 2003 May; 12(3):309-15. PubMed ID: 12698071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.
    Taylor AA; Sunthornyothin S
    Curr Hypertens Rep; 1999 Oct; 1(5):446-53. PubMed ID: 10981104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive drugs in renal failure.
    Albert FW
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S108-12. PubMed ID: 7898089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antihypertensive therapy in chronic kidney disease: what targets and how to reach them].
    Bock A
    Ther Umsch; 2018; 75(6):365-369. PubMed ID: 30880625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephroprotection by antihypertensive agents.
    Schmieder RE
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy.
    Epstein M
    Ren Fail; 1996 Nov; 18(6):813-32. PubMed ID: 8948517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
    Thomas MC; Atkins RC
    Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update in pharmacologic treatment of hypertension.
    Ferdinand KC
    Cardiol Clin; 2001 May; 19(2):279-94, v. PubMed ID: 11407110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of hypertension in kidney diseases].
    Ferrari P; Bonny O
    Praxis (Bern 1994); 2003 Dec; 92(50):2145-52. PubMed ID: 14708253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.